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Background
Xolair ® (omalizumab) has been approved in Canada since
2004 for the treatment of moderate to severe persistent
allergic asthma in patients 12 years of age. The use of
omalizumab in severe persistent allergic asthma may lead
to decrease health care utilization through emergency
room (ER) visits, hospitalizations, visits to health care pro-
viders, as well as, decrease the use of corticosteroids and
improve the overall quality of life (QoL).
Methods
Data collected from patient enrollment and QoL question-
naires completed at specific intervals during treatment
with omalizumab at our large tertiary care clinic from
2004 to 2014 was analyzed.
Results
A steady number of patients were enrolled each year since
2004, showing its greatest increase in enrollment numbers
since 2012. Our data indicates that the majority of patients
improved with significantly less asthma exacerbation, less
ER visits and hospitalizations, less use of inhaled and oral
corticosteroids and better QoL.
Conclusion
Omalizumab is effective in the treatment of moderate and
severe allergic asthma. It improves QoL and reduces
asthma exacerbations, ER visits and hospitalizations, and
use of inhaled and oral corticosteroids.
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